APA (7th ed.) Citation

PP, N., H, H., M, M., M, L., D, G., A, A., . . . GV, M. (2026). Optimizing metabolic management on integrase-based ART (OPTIMAR): Study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk. Trials, 27(1), . https://doi.org/10.1186/s13063-026-09723-2

Chicago Style (17th ed.) Citation

PP, Nyein, et al. "Optimizing Metabolic Management on Integrase-based ART (OPTIMAR): Study Protocol for a 2 × 2 Factorial, Randomised, Double-blind Placebo-controlled Trial to Compare the Addition of Dapagliflozin Versus Placebo, and Rosuvastatin Plus Ezetimibe Versus Pitavastatin, in People with HIV on Integrase Strand Transfer Inhibitor-based Antiretroviral Therapy with Elevated Metabolic Risk." Trials 27, no. 1 (2026). https://doi.org/10.1186/s13063-026-09723-2.

MLA (9th ed.) Citation

PP, Nyein, et al. "Optimizing Metabolic Management on Integrase-based ART (OPTIMAR): Study Protocol for a 2 × 2 Factorial, Randomised, Double-blind Placebo-controlled Trial to Compare the Addition of Dapagliflozin Versus Placebo, and Rosuvastatin Plus Ezetimibe Versus Pitavastatin, in People with HIV on Integrase Strand Transfer Inhibitor-based Antiretroviral Therapy with Elevated Metabolic Risk." Trials, vol. 27, no. 1, 2026, https://doi.org/10.1186/s13063-026-09723-2.